**Author details**

Minyahil Alebachew Woldu\*, Atalay Mulu Fentie and Tamrat Assefa Tadesse Department of Pharmacology and Clinical Pharmacy, Addis Ababa University, Addis Ababa, Ethiopia

\*Address all correspondence to: minyahil.alebachew@aau.edu.et

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**39**

ajh.24402.

*Treatment Approaches of Multiple Myeloma DOI: http://dx.doi.org/10.5772/intechopen.97390*

[1] Kumar SK, Callander NS, Alsina M,

European Myeloma Network guidelines

for the management of multiple myeloma-related complications. Haematologica. 2015;100(10):1254- 1266. doi: 10.3324/haematol.2014.

[8] Terpos E, Engelhardt M, Cook G,

Stathopoulos I, et al. Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN). Leukemia.

2020;34(8):2000-11. doi: https://doi. org/10.1038/s41375-020-0876-z.

[9] Gay F, Engelhardt M, Terpos E, Wäsch R, Giaccone L, Auner HW, et al. From transplant to novel cellular therapies in multiple myeloma:

2018;103(2):197. doi: 10.3324/

haematol.2017.174573.

org/10.1002/ajh.25791.

2013;10:12-15.

Book. 2013.

[11] San-Miguel JF, Paiva B,

European Myeloma Network guidelines and future perspectives. Haematologica.

[10] Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, riskstratification and management. American journal of hematology. 2020;95(5):548-67. doi: https://doi.

Gutiérrez NC. New tools for diagnosis and monitoring of multiple myeloma. Am Soc Clin Oncol Educ Book.

[12] Fowler NH, Staudt LM, Bradner J. Hot Pathways for Targeted Therapy of B-Cell Malignancies. American Society of Clinical Oncology Educational

[13] Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos M-V, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. The lancet oncology. 2014;15(12):e538-e48.

Gay F, Mateos M-V, Ntanasis-

117176.

Chandler JC, et al. Multiple myeloma, version 3.2017, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2017;15(2):230-69. doi:

[2] Kuehl WM, Bergsagel PL. Early genetic events provide the basis for a clinical classification of multiple myeloma. ASH Education Program Book. 2005;2005(1):346-52. doi: https://

doi.org/10.1182/asheducation-

[3] Willrich MA, Katzmann JA. Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias. Clinical Chemistry and Laboratory Medicine (CCLM). 2016;54(6):907-19. doi: https://doi. org/10.1515/cclm-2015-0580.

[4] Harousseau J-L, Dreyling M. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and

[5] Moreau P, San Miguel J, Ludwig H, Schouten H, Mohty M, Dimopoulos M, et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2013;24:vi133-vi7. doi:

[6] Rajkumar SV. Multiple myeloma: 2016 update on diagnosis, riskstratification, and management. American journal of hematology. 2016;91(7):719-734. doi: 10.1002/

[7] Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, et al.

follow-up. Annals of Oncology. 2010;21:v155-v1v7. doi: 10.1093/

annonc/mdq178.

10.1093/annonc/mdt297.

Atanackovic D, Biermann JS,

https://doi.org/10.6004/

jnccn.2017.0023.

**References**

2005.1.346.

*Treatment Approaches of Multiple Myeloma DOI: http://dx.doi.org/10.5772/intechopen.97390*
